Recent Advancements in the Clinical Evaluation of Plant-Derived Anticancer Compounds

  • Jayabalan Shilpha
  • Lakkakula Satish
  • Manikandan Ramesh


Cancer is a chief global health burden and the leading cause of human death worldwide next to heart diseases. The alarming rise in the mortality rate owing to cancer has driven the chase for anticancer agents to effectively combat this disease. Searching for novel and efficient compounds of natural origin has been a major aspect of concerns because they exhibit less toxic side effects. Numerous secondary metabolites from plants and their semisynthetic analogs have been identified as an excellent, novel lead structures in developing promising anticancer agents. In the current scenario, several successful anticancer drugs and their derivatives have been obtained from plant sources, and many of them are in clinical trials. Phytocompounds such as vinca alkaloids, taxanes, podophyllotoxin, camptothecin, homoharringtonine, and their derivatives have appreciably influenced cancer research on many facets. Likewise, some of the other plant-derived anticancer agents including omacetaxine mepesuccinate, ingenol mebutate, β-lapachone, flavopiridol, curcumin, etc. are currently being under phase I and II clinical trials, either individually or in concert with other anticancer agents for the treatment of a broad range of tumors like lymphomas, leukemias, and solid tumors. Customary anticancer drug discovery has targeted mainly on the cytotoxic agents that hamper metabolic pathways critical to cell division. However, during recent years, several molecular target-based compounds have been emerged concentrating on other cellular process of cancer cells such as apoptosis, metastasis, angiogenesis, etc. Hence, the present anticancer drug discovery involves high-throughput screening of phytocompounds against a series of such molecular targets. The present chapter discusses the clinical evidences of some important phytocompounds of anticancer plants, overview of their current clinical status, and recent advances in their molecular mechanism of action.


Anticancer agents Cytotoxic agents Clinical trials Natural compounds Secondary metabolites 


  1. Aggarwal BB, Sundaram C, Malani N, Ichikawa H (2007) Curcumin: the Indian solid gold. Adv Exp Med Biol 595:1–75CrossRefPubMedGoogle Scholar
  2. Akhtar MS, Birhanu G, Demisse S (2014) Antimicrobial activity of Piper nigrum L. and Cassia didymobotyra L. leaf extract on selected food borne pathogens. Asian Pac J Trop Dis 4:S911–S919CrossRefGoogle Scholar
  3. Anonymous (2014) A study to assess the effectiveness of the combination of carboplatin, paclitaxel, bevacizumab and combretastatin (CA4P) in patients with chemotherapy naive lung cancer. BioPortfolio 3:31–32Google Scholar
  4. Ansari J, Inamdar N (2010) The promise of traditional medicines. Int J Pharmacol 6:808–812CrossRefGoogle Scholar
  5. Arumugam G, Swamy MK, Sinniah UR (2016) Plectranthus amboinicus (Lour.) Spreng: botanical, phytochemical, pharmacological and nutritional significance. Molecules 21:369. CrossRefPubMedGoogle Scholar
  6. Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR, Kim AL (2007) Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 224:274–283CrossRefPubMedPubMedCentralGoogle Scholar
  7. Bachner M, De Santis M (2008) Vinflunine in the treatment of bladder cancer. Ther Clin Risk Manag 4:1243–2125CrossRefPubMedPubMedCentralGoogle Scholar
  8. Bailey HH, Attia S, Love RR, Fass T, Chappell R, Tutsch K, Harris L, Jumonville A, Hansen R, Shapiro GR, Stewart JA (2008) Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer. Cancer Chemother Pharmacol 62:149–157CrossRefPubMedGoogle Scholar
  9. Balachandran P, Govindarajan R (2005) Cancer-An ayurvedic perspective. Pharmacol Res 51:19–30CrossRefPubMedGoogle Scholar
  10. Banerjee S, Wang Z, Mohammad M, Sarkar FH, Mohammad RM (2008) Efficacy of selected natural products as therapeutic agents against cancer. J Nat Prod 71:492–496CrossRefPubMedGoogle Scholar
  11. Cai YJ, Lu JJ, Zhu H, Xie H, Huang M, Lin LP, Zhang XW, Ding J (2008) Salvicine triggers DNA double-strand breaks and apoptosis by GSH-depletion driven H2O2 generation and topoisomerase II inhibition. Free Radic Biol Med 45:627–635CrossRefPubMedGoogle Scholar
  12. Chanvorachote P, Chamni S, Ninsontia C, Phiboonchaiyanan PP (2016) Potential anti-metastasis natural compounds for lung cancer. Anticancer Res 36:5707–5718CrossRefPubMedGoogle Scholar
  13. Choi H, Cho SY, Pak HJ, Kim Y, Choi J, Lee YJ, Gong BH, Kang YS, Han T, Choi G, Cho Y, Lee S, Ryoo D, Park H (2017) NPCARE: database of natural products and fractional extracts for cancer regulation. J Cheminform 9:2. CrossRefPubMedPubMedCentralGoogle Scholar
  14. Cichewicz RH, Kouzi SA (2004) Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. Med Res Rev 24:90–114CrossRefPubMedGoogle Scholar
  15. Cragg GM, Pezzuto JM (2016) Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents. Med Princ Pract 25:41–59CrossRefPubMedGoogle Scholar
  16. Da Rocha AB, Lopes RM, Schwartsmann G (2001) Natural products in anticancer therapy. Curr Opin Pharmacol 1:364–369CrossRefPubMedGoogle Scholar
  17. Delmonte A, Sessa C (2009) AVE8062: a new combretastatin derivative vascular disrupting agent. Expert Opin Investig Drugs 18:1541–1548CrossRefPubMedGoogle Scholar
  18. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R (2008) Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14:4491–4499CrossRefPubMedGoogle Scholar
  19. Dias DA, Urban S, Roessner U (2012) A historical overview of natural products in drug discovery. Metabolites 2:303–336CrossRefPubMedPubMedCentralGoogle Scholar
  20. Eisenbrand G, Hippe F, Jakobs S, Muehlbeyer S (2004) Molecular mechanisms of indirubin and its derivatives: novel anticancer molecules with their origin in traditional Chinese phytomedicine. J Cancer Res Clin Oncol 130:627–635CrossRefPubMedGoogle Scholar
  21. Fallen RS, Gooderham M (2012) Ingenol mebutate: an introduction. Skin Ther Lett 17:1–3Google Scholar
  22. Fridlender M, Kapulnik Y, Koltai H (2015) Plant derived substances with anticancer activity: from folklore to practice. Front Plant Sci 6:799. CrossRefPubMedPubMedCentralGoogle Scholar
  23. Fulda S (2009) Betulinic acid: a natural product with anticancer activity. Mol Nutr Food Res 53:140–146CrossRefPubMedGoogle Scholar
  24. Gezahegn Z, Akhtar MS, Woyessa D, Tariku Y (2015) Antibacterial potential of Thevetia peruviana leaf extracts against food associated pathogens. J Coast Life Med 3:150–157Google Scholar
  25. Hert J, Irwin JJ, Laggner C, Keiser MJ, Shoichet BK (2009) Quantifying biogenic bias in screening libraries. Nat Chem Biol 5:479–483CrossRefPubMedPubMedCentralGoogle Scholar
  26. Iveta V, Michaela M, Petr H, Rene K, Eva F, Marie S (2013) The anticancer drug ellipticine induces cytochromes P450 1A1, 1A2 and 3A, cytochrome b5 and NADPH: cytochrome P450 oxidoreductase in rat liver, kidney and lung. Int J Electrochem Sci 8:1586–1597Google Scholar
  27. Jaroch K, Karolak M, Górski P, Jaroch A, Krajewski A, Ilnicka A, Sloderbach A, Stefanski T, Sobiak S (2016) Combretastatins: in vitro structure-activity relationship, mode of action and current clinical status. Pharmacol Rep 68:1266–1275CrossRefPubMedGoogle Scholar
  28. Johnson JJ, Mukhtar H (2007) Curcumin for chemoprevention of colon cancer. Cancer Lett 255:170–181CrossRefPubMedGoogle Scholar
  29. Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253–265CrossRefPubMedGoogle Scholar
  30. Kapoor S (2012) Emerging role of berbamine as an anti-cancer agent in systemic malignancies besides chronic myeloid leukemia. J Zhejiang Univ Sci B 13:761–762CrossRefPubMedPubMedCentralGoogle Scholar
  31. Khaled M, Belaaloui G, Jiang ZZ, Zhu X, Zhang LY (2017) Deoxypodophyllotoxin, a semi-synthetic compound from Dysosma versipellis, induces selective cell death in human breast cancer cell lines. Med Chem Res 26:1241–1258CrossRefGoogle Scholar
  32. Khan M, Maryam A, Zhang H, Mehmood T, Ma T (2016) Killing cancer with platycodin D through multiple mechanisms. J Cell Mol Med 20:389–402CrossRefPubMedGoogle Scholar
  33. Khazir J, Mir BA, Pilcher L, Riley DL (2014) Role of plants in anticancer drug discovery. Phytochem Lett 7:173–181CrossRefGoogle Scholar
  34. Khazir J, Singh PP, Doma MR, Syed S, Hyder I, Gousia C, Ajay M, Alam MS, Saxena AK, Arvinda S, Gupta BD, Kumar HMS (2013) Synthesis and anticancer activity of novel spiro-isoxazoline and isoxazolidine derivatives of α-santonin. Eur J Med Chem 63:279–289CrossRefPubMedGoogle Scholar
  35. Kim S, Hwang BY, Su BN, Chai H, Mi Q, Kinghorn AD, Wild R, Swanson SM (2007) Silvestrol, a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in LNCaP cells through the mitochondrial/apoptosome pathway without activation of executioner caspase-3 or −7. Anticancer Res 27:2175–2183PubMedPubMedCentralGoogle Scholar
  36. Kutkowska J, Strzadala L, Rapak A (2017) Synergistic activity of sorafenib and betulinic acid against clonogenic activity of non-small cell lung cancer cells. Cancer Sci 108:2265–2272CrossRefPubMedPubMedCentralGoogle Scholar
  37. Lakhanpal S, Donehower RC, Rowinsky EK (2001) Phase II study of 4-ipomeanol, a naturally occurring alkylating furan, in patients with advanced hepatocellular carcinoma. Investig New Drugs 19:69–76CrossRefGoogle Scholar
  38. Lansky EP, Newman RA (2007) Punica granatum (pomegranate) and its potential for prevention and treatment of inflammation and cancer. J Ethnopharmacol 19:177–206CrossRefGoogle Scholar
  39. Lee KH, Xiao Z (2012) Podophyllotoxins and analogs. In: Cragg GM, Kingston DGI, Newman DJ (eds) Anticancer agents from natural products, 2nd edn. CRC Taylor and Francis, Boca Raton, pp 95–122Google Scholar
  40. Liu GY, Bu X, Yan H, Jia WWG (2007) 20S-Protopanaxadiol-induced programmed cell death in glioma cells through caspase-dependent and independent pathways. J Nat Prod 70:259–265CrossRefPubMedGoogle Scholar
  41. Liu JM, Chen LT, Chao Y, Li AF, Wu CW, Liu TS, Shiah HS, Chang JY, Chen JD, Wu HW, Lin WC, Lan C, Whang-Peng J (2002) Phase II and pharmacokinetic study of GL331 in previously treated Chinese gastric cancer patients. Cancer Chemother Pharmacol 49:425–428CrossRefPubMedGoogle Scholar
  42. Mamtani R, Vaughn DJ (2011) Vinflunine in the treatment of advanced bladder cancer. Exp Rev Anticancer Ther 11:13–20CrossRefGoogle Scholar
  43. Marie S, Jitka P, Eva M, Jitka U, Vilim S, Zdenek D, Eva F (2012) Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5. Toxicology 302:233–241CrossRefGoogle Scholar
  44. May M (2014) Statistics: attacking an epidemic. Nature 509:S50–S51CrossRefPubMedGoogle Scholar
  45. Mi Q, Lantvit D, Reyes-Lim E, Chai H, Pezzuto JM, Kinghorn AD, Swanson SM (2003) Pervilleine F, a new tropane alkaloid aromatic ester that reverses multidrug resistance. Anticancer Res 23:3607–3615PubMedGoogle Scholar
  46. Millimouno FM, Dong J, Yang L, Li J, Li X (2014) Targeting apoptosis pathways in cancer and perspectives with natural compounds from mother nature. Cancer Prev Res 7:1081–1107CrossRefGoogle Scholar
  47. Min KJ, Kwon TK (2014) Anticancer effects and molecular mechanisms of epigallocatechin-3-gallate. Integr Med Res 3:16–24CrossRefPubMedGoogle Scholar
  48. Mohanty SK, Swamy MK, Sinniah UR, Anuradha M (2017) Leptadenia reticulata (Retz.) Wight & Arn. (Jivanti): botanical, agronomical, phytochemical, pharmacological, and biotechnological aspects. Molecules 22:1019. CrossRefGoogle Scholar
  49. Muhtasib GH, Hmadi R, Kareh M, Tohme R, Darwiche N (2015) Cell death mechanisms of plant-derived anticancer drugs: beyond apoptosis. Apoptosis 20:1531–1562CrossRefGoogle Scholar
  50. Mullauer FB, Kessler JH, Medema JP (2010) Betulinic acid, a natural compound with potent anticancer effects. Anti-Cancer Drugs 21:215–227CrossRefPubMedGoogle Scholar
  51. Narang AS, Desai DS (2009) Anticancer drug development. In: Lu Y, Mahato RI (eds) Pharmaceutical perspectives of cancer therapeutics. Springer, New York, pp 65–66Google Scholar
  52. Newman DJ, Cragg GM (2012) Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 75:311–335CrossRefPubMedPubMedCentralGoogle Scholar
  53. Newman DJ, Cragg GM, Snader KM (2003) Natural products as sources of new drugs over the period 1981–2002. J Nat Prod 66:1022–1037CrossRefPubMedGoogle Scholar
  54. Newman DJ, Cragg GM (2007) Natural products as sources of new drugs over the last 25 years. J Nat Prod 70:461–477CrossRefPubMedGoogle Scholar
  55. NIH (2013) Evaluation of 20% betulinic acid ointment for treatment of Dysplastic nevi (moderate to severe dysplasia). Assessed 5 Oct 2017
  56. Nobili S, Lippi D, Witortd E, Donninic M, Bausi L, Minia E (2009) Sergio capacciolic natural compounds for cancer treatment and prevention. Pharmacol Res 59:365–378CrossRefPubMedGoogle Scholar
  57. Oberlies NH, Kroll DJ (2004) Camptothecin and taxol: historic achievements in natural products research. J Nat Prod 67:129–135CrossRefPubMedGoogle Scholar
  58. Pan L, Chai H, Kinghorn AD (2010) The continuing search for antitumor agents from higher plants. Phytochem Lett 3:1–8CrossRefPubMedPubMedCentralGoogle Scholar
  59. Pan S, Zhou S, Gao S, Yu Z, Zhang S, Tang M, Sun J, Ma D, Han Y, Fong W, Ko K (2013) New perspectives on how to discover drugs from herbal medicines: CAM’s outstanding contribution to modern therapeutics. Evidence-Based Compl Altern Med 2013:627375. CrossRefGoogle Scholar
  60. Panda AK, Chakraborty D, Sarkar I, Khan T, Sa G (2017) New insights into therapeutic activity and anticancer properties of curcumin. J Exp Pharmacol 9:31–45CrossRefPubMedPubMedCentralGoogle Scholar
  61. Patterson DM, Zweifel M, Middleton MR, Price PM, Folkes LK, Stratford MR, Ross P, Halford S, Peters J, Balkissoon J, Chaplin DJ, Padhani AR, Rustin GJ (2012) Phase I clinical and pharmacokinetic evaluation of the vascular disrupting agent OXi4503 in patients with advanced solid. Clin Cancer Res 18:415–1425CrossRefGoogle Scholar
  62. Quesada AR, Munoz-Chapuli R, Medina MA (2006) Anti-angiogenic drugs: from bench to clinical trials. Med Res Rev 26:483–530CrossRefPubMedGoogle Scholar
  63. Rahier NJ, Thomas CJ, Hecht SM (2005) Camptothecin and its analogs. In: Cragg GM, DGI K, Newman DJ (eds) Anticancer agents from natural products. Brunner-Routledge Psychology Press, Taylor and Francis Group, Boca Raton, pp 5–21Google Scholar
  64. Rivera M, Ramos Y, Rodroaguez-Valentõan M, Loapez-Acevedo S, Cubano LA, Zou J, Zhang Q, Wang G, Boukli NM (2017) Targeting multiple pro-apoptotic signaling pathways with curcumin in prostate cancer cells. PLoS One 12:e0179587CrossRefPubMedPubMedCentralGoogle Scholar
  65. Ruan S, Jia F, Li J (2017) Potential antitumor effect of harmine in the treatment of thyroid cancer. Evidence-Based Compl Altern Med 2017:9402615. CrossRefGoogle Scholar
  66. Saklani A, Kutty SK (2008) Plant-derived compounds in clinical trials. Drug Discov Today 13:161–171CrossRefPubMedGoogle Scholar
  67. Sargent JM, Elgie AW, Williamson CJ, Hill BT (2003) Ex-vivo effects of the dual topoisomerase inhibitor tafluposide (F11782) on cells isolated from fresh tumor samples taken from patients with cancer. Anti-Cancer Drugs 14:467–473CrossRefPubMedGoogle Scholar
  68. Schmidt M, Betti G, Hensel A (2007) Saffron in phytotherapy: pharmacology and clinical use. Wien Med Wochenschr 157:315–409CrossRefPubMedGoogle Scholar
  69. Shapiro GI (2004) Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res 10:4270–4275CrossRefGoogle Scholar
  70. Shukla S, Meeran SM, Katiyar SK (2014) Epigenetic regulation by selected dietary phytochemicals in cancer chemoprevention. Cancer Lett 355:9–17CrossRefPubMedPubMedCentralGoogle Scholar
  71. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29CrossRefPubMedGoogle Scholar
  72. Silasi DA, Alvero AB, Rutherford TJ, Brown D, Mor G (2009) Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs. Expert Opin Pharmacother 10:1059–1067CrossRefPubMedGoogle Scholar
  73. Singh S (2007) From exotic spice to modern drug. Cell 130:765–776CrossRefPubMedGoogle Scholar
  74. Singh S, Sharma B, Kanwar SS, Kumar A (2016) Lead phytochemicals for anticancer drug development. Front Plant Sci 7:1667. CrossRefPubMedPubMedCentralGoogle Scholar
  75. Sivakumar G (2013) Colchicine semisynthetics: chemotherapeutics for cancer. Curr Med Chem 20:892–898PubMedGoogle Scholar
  76. Slovackova J, Smarda J, Smardova J (2012) Roscovitine-induced apoptosis of H1299 cells depends on functional status of p53. Neoplasma 59:606–612CrossRefPubMedGoogle Scholar
  77. Subramani R, Gonzalez E, Arumugam A, Nandy S, Gonzalez V, Medel J, Camacho F, Ortega A, Bonkoungou S, Narayan M, Ak D, Lakshmanaswamy R (2016) Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition. Sci Rep 6:19819CrossRefPubMedPubMedCentralGoogle Scholar
  78. Swamy MK, Akhtar MS, Sinniah UR (2016) Antimicrobial properties of plant essential oils against human pathogens and their mode of action: an updated review. Evidence-Based Compl Altern Med 2016:21. CrossRefGoogle Scholar
  79. Swamy MK, Arumugam G, Kaur R, Ghasemzadeh A, Yusoff MM, Sinniah UR (2017) GC-MS based metabolite profiling, antioxidant and antimicrobial properties of different solvent extracts of Malaysian Plectranthus amboinicus leaves. Evidence-Based Compl Altern Med 2017:1517683. CrossRefGoogle Scholar
  80. Swamy MK, Pokharen N, Dahal S, Anuradha M (2011) Phytochemical and antimicrobial studies of leaf extract of Euphorbia neriifolia. J Med Plant Res 5:5785–5788Google Scholar
  81. Swamy MK, Sinniah UR (2016) Patchouli (Pogostemon cablin Benth.): botany, agrotechnology and biotechnological aspects. Ind Crop Prod 87:161–176CrossRefGoogle Scholar
  82. Verma AK, Singh RR (2010) Induced dwarf mutant in Catharanthus roseus with enhanced antibacterial activity. Indian J Pharm Sci 72:655–657CrossRefPubMedPubMedCentralGoogle Scholar
  83. Westwell AD (2003) Novel antitumour molecules. Drug Discov Today 8:47–50CrossRefGoogle Scholar
  84. Willmann M, Wacheck V, Buckley J, Nagy K, Thalhammer J, Paschke R, Triche T, Jansen B, Selzer E (2009) Characterization of NVX-207, a novel betulinic acid-derived anticancer compound. Eur J Clin Investig 39:384–394CrossRefGoogle Scholar
  85. Wurz GT, Kao CJ, DeGregorio MW (2016) Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Ther Adv Med Oncol 8:4–31CrossRefPubMedPubMedCentralGoogle Scholar
  86. Xie S, Zhou J (2017) Harnessing plant biodiversity for the discovery of novel anticancer drugs targeting microtubules. Front Plant Sci 8:720. CrossRefPubMedPubMedCentralGoogle Scholar
  87. Yang GW, Jiang JS, Lu WQ (2015) Ferulic acid exerts anti-angiogenic and anti-tumor activity by targeting fibroblast growth factor receptor 1-mediated angiogenesis. Int J Mol Sci 16:24011–24031CrossRefPubMedPubMedCentralGoogle Scholar
  88. Yeruva L, Pierre KJ, Elegbede A, Wang RC, Carper SW (2007) Perillyl alcohol and perillic acid induced cell cycle arrest and apoptosis in non-small cell lung cancer cells. Cancer Lett 257:216–226CrossRefPubMedGoogle Scholar
  89. Zhan YP, Hyang XE, Cao J, Lu YY, Wu XY, Liu J, Xu X, Xiang J, Ye LH (2012) Clinical safety and efficacy of kanglaite (coix seed oil) injection combined with chemotherapy in treating patients with gastric cancer. Asian Pac J Cancer Prev 13:5319–5321CrossRefPubMedGoogle Scholar
  90. Zhang HM, Zhao L, Li H, Xu H, Chen WW, Tao L (2014) Research progress on the anticarcinogenic actions and mechanisms of ellagic acid. Cancer Biol Med 11:92–100PubMedPubMedCentralGoogle Scholar
  91. Zhu HL (2011) Resveratrol and its analogues: promising antitumor agents. Anti Cancer Agents Med Chem 11:479–490CrossRefGoogle Scholar
  92. Zuo M, Li Y, Wang H, Zhou J, Li H, Liu H, Liu H, Xin H, Zhang S, Chen X (2008) The antitumor activity of meisoindigo against human colorectal cancer HT-29 cells in vitro and in vivo. J Chemother 20:728–733Google Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2017

Authors and Affiliations

  • Jayabalan Shilpha
    • 1
  • Lakkakula Satish
    • 1
    • 2
    • 3
  • Manikandan Ramesh
    • 1
  1. 1.Department of Biotechnology, Science CampusAlagappa UniversityKaraikudiIndia
  2. 2.Department of Biotechnology EngineeringBen-Gurion University of NegevBeer ShevaIsrael
  3. 3.The Jacob Blaustein Institutes for Desert ResearchBen-Gurion University of the Negev, Bergman CampusBeer ShevaIsrael

Personalised recommendations